Abstract
The paucity of active medical therapies for advanced prostate cancer underlies a critical need for clinical research in this area. Multiple new treatments are being evaluated, including therapies that target adrenal androgens, such as abiraterone; new chemotherapies, such as the oral platinum analog, satraplatin, and an epothilone analog, ixabepilone; combinations of chemotherapy with other agents, such as the VEGF inhibitor, bevacizumab, and calcitriol; as well as multiple immunotherapeutics, including sipuleucel-T, GVAX and ipilimumab. This review will highlight the promise of these new approaches and the challenges to their development.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 259-268 |
| Number of pages | 10 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 8 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2008 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Abiraterone
- Adrenal androgens
- Atrasentan
- Bevacizumab
- Calcitriol
- Castrate-resistant prostate cancer
- Chemotherapy
- GVAX
- Immunotherapy
- Ipilimumab
- Ixabepilone
- Phase II
- Satraplatin
- Sipuleucel-T
Fingerprint
Dive into the research topics of 'Therapies in development for castrate-resistant prostate cancer'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS